An American privately-held company, it is a pioneer in the field of biosimilars and complex generic drugs.
Since 1995, they have been a leading developer of high-quality biosimilar therapeutics.
Our technological expertise and infrastructure enable full-cycle product development, commercial manufacturing and product commercialization.
Improving patient benefit by expanding access to biologic drugs
This company focuses on biosimilars and new antibody therapeutics with solid foundation and is rapidly advancing to be a strong player in the global biopharmaceutical market.
Striving to improve accessibility and affordability for existing biologic drugs and research on unmet medical needs to provide cure for orphan drugs.
Products
- Invested in past years to establish a strong infrastructure for efficient development and highest quality manufacturing
- Developed a large portfolio of manufacturing technologies which were successfully commercialized
- FDA and EMA-compliant Manufacturing plant
- Rich portfolio of mAbs APIs and manufacturing technologies – including IP
- Next generation biosimilar products under development for global markets – will be one of the first in the market
Product portfolio part list :
Glatiramer Acetate (Copaxone®)
Infliximab (Remicade®)
Adalimumab (Humira®)
Bevacizumab (Avastin®)
Interferon beta-1b
Denosumab (Prolia® and Xgeva®)